| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | Z20OC92TDI |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Receptor protein-tyrosine kinase erbB-2 inhibitor |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Biliary Tract Neoplasms | 4 | D001661 | FDA |
| Biliary Tract Neoplasms | 4 | D001661 | ClinicalTrials |
| Neoplasms | 4 | D009369 | ClinicalTrials |
| Biliary Tract Neoplasms | 4 | D001661 | ClinicalTrials |
| Breast Neoplasms | 3 | D001943 | ClinicalTrials |
| Breast Neoplasms | 3 | D001943 | ClinicalTrials |
| Stomach Neoplasms | 2 | D013274 | ClinicalTrials |
| Hemangiosarcoma | 2 | D006394 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4650256 |
| FDA SRS | Z20OC92TDI |
CONTENTS